Austin, TX (April 10, 2025) —Prodigy Health is proud to announce the availability of Alhemo (concizumab), an innovative therapy developed by Novo Nordisk for patients with hemophilia A or B with inhibitors. Recently approved in the United States, European Union, Canada, and Australia, Alhemo represents a cutting-edge advancement in hemophilia management.
Alhemo is a monoclonal antibody designed to target and inhibit the tissue factor pathway inhibitor (TFPI), a key regulator in the coagulation process. By modifying this pathway, Alhemo offers routine prophylaxis to reduce the frequency of bleeding episodes in patients aged 12 years and older. Its subcutaneous administration provides a convenient and effective alternative to traditional factor-based treatments.
“Alhemo is a valuable addition to our portfolio, offering patients a prefilled subcutaneous pen for hemophilia B and A with inhibitors," said Keith Patek, President at Prodigy Health. "We are proud to ensure seamless access to this new therapy in support of healthcare providers and their patients.
With a strong focus on efficiency, data-driven insights, and an unwavering commitment to compassionate service, Prodigy Health continues to lead in specialty pharmaceutical distribution, making next-generation therapies like Alhemo accessible, reliable, and patient-centric.
For more information on Alhemo’s availability and ordering through Prodigy Health, please visit prodigyhealth.com or call 877-693-4376.
